An acute toxicity test of Bio-synthesized Organic Germanium

- 1. Mouse An acute oral toxicity test
- 2. Rat An acute oral toxicity test

September 15, 1994

Experimental Animal Laboratory,

Research Institute of Animal Medicine College of Veterinary Medicine,

Chungbuk National University, Korea

Report

This report submit as a research paper about acute oral toxicity test to mouse and rat of the GERANTI (Biosynthesized Organic Germanium) that was manufactured by Geranti Pharm Ltd.

September 15, 1994

Chief researcher: A college of veterinary medicine, Chungbuk University.

A dean professor Kim chang ki

Research institution: The research institute of animal medicine, Chungbuk University

A head assistant professor Ji Cha Ho

Responsible person of research: The research institution of animal Medicine,

A college of veterinary medicine, Chungbuk University.

An assistant professor Kang Jong Ku

1. Self Description of The veterinary medicine research institute

Title	1	Immuno-enhanceme	ent Effects of the	GERANTI (BIO-
	synthesized Organi	am Ltd. president	Shon Tsano Lik	
Client		Daiji B/D Yuksamdo		Sacul
		search institution :		
5			A conege of ven	ennary medicine,
Research	Chungbuk Univers			·
institution		sindong chongju Ch		
		researcher : A dear		
		tute was, depend o		
		ng to the whole of li		
		dical science. Esta		
Purpose		een the research		
		ıltural medicines,		
		new disease mode		
	animal, as a watch	nman to defense the	health of man and	animals.
	This research inst	titute, relating to th	e National of Sani	tation and Safety
	Research Institute	65050-188 number	(Feb. 24, 1994) ha	s been studied on
Research item	the efficacy of a n	nedicine, pharmaco	ology test, in addition	on to the general-
	toxicity test, genet	ic-toxicity test, a ger	nerative-toxicity tes	t,
	a local-toxicity test	, antigenic test etc.		
		nal medicine resea	rch institute, a colle	ge of vetorinary
	medicine, Chung		•	
Responsible		person of the	animal manageme	ent an assistant
person	professor Kang Jo			
		Saesindong Chongju	. Chunabuk	
		person of the		ent an assistant
Charge of Animal	professor Kang Jo		amma managom	
Control		Saesindong Chongji	ı Chunghuk	
		aster course, 2nd to		terinary medicine
	department, Chun		onn, a concept of ve	otomialy mediane
	Lee Jong Sung:	gour offiversity	10	
Member of	Oh Myung Ho:			
Researchers	Lee Won Hyung:	<u></u>		
			urse, 1 st term,	a callege of
	Jung Jae Hwa			a college of
		e Chungbuk Univ		adana andisian
		: 3rd year studen	t, a college of vet	ennary medicine,
	Chungbuk Univers	sity	· · · · · · · · · · · · · · · · · · ·	
Research assistant	Pak Hak Su	<u>:</u>	 	
		: 2nd year studen	t, a college of vet	lennary medicine,
	Chungbuk Univers	sity		
	Pak Sun Hee	<u>:</u>	**	
	No. of		10	
	Researcher			
	Ground		600 m'	
	Ciouna	·		
The main feasilities	Cround	Puilding	veterinary	Breeding room
The main facilities	Cround	Building	veterinary college(1)	
The main facilities	Building			Breeding room of animals(1) 178.2
The main facilities		Building Area(m') The date of	college(1)	of animals(1)

2. The main equipment and basic facilities

- 1. Paraffin temperature maintain apparatus
- 2. Automatic tissue handling apparatus
- 3. Embedding center
- 4. Auto clave
- 5. Slide heater
- 6. Microtome for tissue of a living body
- 7. Paraffin oven
- 8. Spectrophotometer
- 9. Multi using microscope
- 10. Difference phase Microscope
- 11. Chimograph of recording type
- 12. pH meter
- 13. Clean bench
- 14. CO₂ incubator
- 15. Water bath for constant temperature
- 16. Air- conditioner
- 17. Computer-80286, 80386
- 18. Liquid Nitrogen tank
- 19. Auto dry chemistry analyzer
- 20. Exp. cage for the toxicity of inspiration
- 21. Metabolic cage
- 22. Balance for animals
- 23. Table of dissection for animals
- 24. Self -registering thermometer and hygrometer
- 25. Colony counter
- 26. Coulter counter for bloods
- 27. Breeding apparatus with automatic maintainer of temperature and humidity
- 28. Breeding system of mouse and rat
- 29. Air cleaner

3. The career of researcher

Name: Kang Jong Ku Birthday: Dec 14, 1995

The place of : Chungbuk chongjusi Gaesindong san 48

Work: The animal medicine research institute, a college of veterinary medicine,

Chungbuk University Tel: 0431-261-2607, Fax: 0431-267-3150

Research Career

Nov. 1985-May.1987: Toxicity-Pathology part of Japan Highfox safety research Institute (researcher), Take charge of the safety test and new medicine screening.

Apr. 1988-May.1990: An associated researcher of Japan radiation medicine research institute studies on movement of immuno system by radiant and environment substance.(studies on Division and increase of macrophage)

May.1990-Aug.1990: The new medicine screening part of Japan Highfox new drug research institute, New urug development and toxicity test using diseases model (acute. sub-acute chronic. generation, deformity, mutagenic. antigenic, a responsible researcher)

Sep.1990-Sep.1992: The department of veterinary medicine, full-time instructor, Chungbuk University

Oct. 1992-present: A College of veterinary medicine, an assistant professor Chungbuk University

Acting

Sep. 1990-present: The councilor of the Korean Experimentation animal society.

Sep. 1990-present: The member of the Korean toxicology society.

Sep. 1990-present: The member of the Korean toxicity-pathology society

Sep. 1990-present: The member of the Korean veterinary medicine society.

Sep.1990-present: The councilor of Japan Highfox society for new medicines

Sep.1990-present: The member of Japan society for toxicology and toxicity-pathology.

Mar. 1992-present: National Research Institute of Sanitation and safety, pathology part,

an advisory professor and a co-operation research professor.

4. Published Papers (Recent 5 years)

- 1 Kang J-K., Suzuki,s Nakayama,H. and Goto, N 1989. The multiplication and pathgenicity of plaque mutants of mouse hepatitis virus, MHV, in cultured mouse hepatocytes. Jap. Soc. Vet. Sci. 107:89
- 2 Kang, J-K Azuma, K., Nakayama, H., and Goto, N. 1989. The multiplication of mouse hepatitis virus(MHV-2) mutants in cultured peritoneal macrophage and macrophage-cell line. Jap. Soc. Vet. Sci. 108:93.
- 3. Nakayama, H., Morozumi, M., Kang. J-K., and Goto, N. 1990 Hepatic nodular fibrosis in a dog J Vet. Med. Sci 52(4):829
- 4. Kang Jong-Koo. 1990. Studies on the pathogenicity of mouse hepatitis virus MHV-2, and its mutant strains in vivo and in vitro.(Ph. D. Thesis, University of Tokyo)
- Goto, N., Kawamoto., Kang. J-K., Uchida, K. and Kai, K. 1991. Hepatitogenicity of three plaque purified mutants of hepatotropic mouse hepatitis virus, MHV-2. J. Vet. Med. Sci 53(4): 655
- 6 Kang, J-K 1991 immune responses of peritoneal cavity in mice infected with fulminant mouse hepatitis virus(MHV-2). Korean J. of Lab. Ani. Sci. 7(2):77
- 7 Kang, J-K, 1991. Mouse hepatitis virus(MHV-2) as a model of the liver infected disease in man. Korean J Vet Sci. 7(1):14
- 8. Kang. J-K., 1991. Peritoneal barrier to the spread of mouse hepatitis virus type-2(MHV-2) in mice. Korean J Vet Sci. 7(2):2
- Kang, J-K., 1991. Hepatitis and brain lesion in mice infected with mutants of mouse hepatitis virus type-2(MHV-2). Jour Agr. Sci., Chungbuk Nat'l Univ.9(2):11
- 10. Kim D-J, Han B-S, Cho S-M, Ahn B-W, Moon A, Lee B-Y, Kim C-H Choi K-S, Kang J-K, Lee J-S 1992. The hepatocarcinogenic potential of tamoxifen on the hepatocarcinogenesis induced by dimethylnitrosamine in F344 rats. The report of national institute of safety research 5:261
- 11 Kang J-K, and Kim C-K, 1992 The effects of BCG pretreatment in pet dogs inoculated experimentally with Mycobacterium bovis. Korean J Vet Sci 332(1):117
- 12. Kim D-J. Han B-S, Ahn B-W, Chio K-S, Kang J-K, Lim C-H, 1993. Changes in subppoluation of bronchoalveolar lavage Fluid in the pulmonary fibrosis induced by bleomycin or peplomycin. Korean J. Toxicology 9(2):241
- Kim J-H, Park C-W, Beak Y-G. Lee J-H, Moon B-W, Kim D-J, kang J-K 1993
 Experimental model development for hepatotoxicity and carcinogenesis test induced

- by MHV/or chemicals. The Report of National Institute of Safety Research 6 41
- 14. Kim D-J, Kang J-K, Lee J-S. 1994. Modifying effects of verapamil on the pulmonary lesion induced by bleomycin in rats. Korean J. Toxicol. 10(1):13
- 15. Kim D-J, Kim C-K, Kang J-K, 1994. pathological and immunohistochemical changes caused by spontaneous mouse hepatitis virus infection of ICR mice in a Korean breeding colony. Korean J. Lab. Ani Sci 10(1) 95
- 16. Kang, J-K, and Goto, N 1994 Pathogenicity and multiplication of three mutants of mouse hepatitis virus, MHV-2, in the primary hepatocyte and Kupffer cell cultures. J Vet. Med. Sci. (admitted for publication).
- 17. Kang, J-K, Goto, N. 1994 Response of the cells in the peritoneal cavity and hematopoeitic system to acute infection with mouse hepatitis virus, MHV-2 and its mutants. Hepatology (admitted for publication)

1. An acute toxicity test of Geranti-Germanium in Mouse

Materials and Method

1 Testing Materials

1) Name: Geranti-Germanium

2) Molecular structure: unknown

3) Chemical name unknown

4) Appearance, a yellow powder

5) pH 6~8

6) The condition of storage: under 4 degree C

2 The experimental animal

In this test, we were selected ICR mice, because ICR mice have been used widely in safety test for acute, subacute and chronic toxicity test. And there are many the physiology autopsy and toxicological data on ICR mouse. We were used only healthful mice without the decrease of the weight among the laboratory animal that made quarantine and acclimation in laboratory for a week. The discrimination of individual was append a label that is stated the name of responsible person, the period of test, dosage, the number of mice, test number in cage for breeding

The mice were breed a five head each the cage of breeding in polycarbonate cage (175W× 240L

- × 145Hmm) during the term of testing and acclimation
- 3 The dosage and the test group

We were set up the highest dosage (5000mg per Kg) that can be administered Gerantigermanium into mice. And Geranti-germanium was diluted in the regular rate (0.5 ratio) with distilled water standardizing this dosage and set up the group of five. The composition of the test group, dosage and liquid measure were the following

The material of administration	Test group	Sex	The number of animal	The animal No.	Dosage (mg/:.g)	Administration volume (ml/Kg B.W)
	GA1	М	5	GAM 1 - GAM 5	5,000	20
		F	5	GAF 1 - GAF 5		
	GA2	М	5	GAM 6 - GAM 1.0	2,500	20
		F	5	GAF 6 - GAF 10		
Dilute Geranti	GA3	М	5	GAM 11 - GAM 15	1,250	20
with D. W.		F	5	GAF 11 - GAF 15		
	GA4	М	5	GAM16 - GAM 20	625	20
		F	5	GAF 16 - GAF 20		
	GA5	М	5	GAM21 - GAM 25	312 5	20
		F	5	GAF 21 - GAF 25		
Control group	GA6	М	5	GAM 26 - GAM 30		
(D. W.)	GAO	F	5	GAF 26 - GAF 30	0	20

^{*}G: Intragastrically, A: Acute, M: Male, F: Female

4 The administration of test material

1) The preparation of test solution

We were prepared the test solution that was diluted in distilled water every dosage just before administration and the germanium content measured by phenylfluorone method

2) The route and the method of administration

We were selected oral administration on the basis of the acute toxicity test method. In mice case, administrate in the stomach using the Sonde. The calculation of dosage was fixed on the basis of mice weight. And the powder of Geranti was dissolved in distilled water. It was only distilled water in control group. And the maximum dosage was set up 5000mg per 4.4 administrate to mice.

5 The observation

The day of administration was observed the general symptoms every hour to twelve hours including the change of general state, the symptoms of poisoning, motility appearance, and whether animal was died or not everyday one times from next day to fourteenth day. The body weight was measured three times, just before autopsy (after .14 days) after seventh days and just before the administration on all mice. The LD_{50} was calculated by the method of Litechfield-Wilcoxon using computer program pharmacological calculation system

Result

(1) LD₅₅ value

When this test material was administrated oral on male and female mice, the example of death was not observed in the maximum dose of $5000 \, \mathrm{mg/kg}$ (0.2 ml/10g B.W.). So the calculation of LD₅₀ value was impossible.

(2) The death rate (Table 1)

In case of oral administration, the example of death was not observed during the total period of test in the both sexes.

(3) Clinical symptoms (Table 2)

The clinical symptom was not observed at all tests group for testing period.

(4) The change of body weight (Table 3)

The significant difference of each group was not observed at all tests group for testing period.

(5) The view of autopsy (Table 4)

It was not observed at all the pathological view due to this material in the autopsy on all survival animals.

(6) The histopathological changes

The significant histopathological change was not observed at all due to this material in the autopsy on all survival mice.

Table 1. Mortality of male and female ICR mice administered intragastrically with Geranti-Germanium.

	Dose	Но	urs	afi	er	trea	atm	en				[ay	s a	fter	tre	atr	ner	nt				Final
Sex	(mg/kg)	1	2	3	4	5	6	12	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Mortality
	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	2,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
Male	1,250	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
iviale	625	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	312.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	0(Control)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5.
	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	2,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
Comple	1,250	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
Female	625	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	312.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	0(Control)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5

Table 2 Clinical Findings of Male and Female ICR Mice administered intragastrically with Geranti-Germanium.

M Male, F. Female

N No of animals examined

- No abnormality detected

	Dose	Findiana			F	lour	s af	ter	reat	me	ent			Da	ys	afte	er ti	rea	tme	ent			
Sex	(mg/k_b)	Findings	1	2	3	4	5	6	12	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	5,000	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	2,500	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	1,250	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
M	625	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		•	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	312.5	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	0	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	(Control)	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	5,000	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	2,500	Ν	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		•	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	1,250	Ν	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
F		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
Г	625	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	312.5	Ν	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	0	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	(Control)	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

Table 3. Body Weights of male and Female ICR Mice administered intragastrically with Geranti-germanium (Mean = SD : g)

Sex	Days after			Dose	(mg/kg)		
367	Treatment	5,000	2,500	1,250	625	312 5	control
		25.68	24.96	25.34	25.08	25.48	25 56
	0	= 0 36	= 040	= 0 52	± 0 45	± 0 73	: 0 59
		(5)	(5)	(5)	(5)	(5)	(5)
		33 38	30.58	33.90	33.02	30.80	29 36
Male	7	± 2.56	± 4 10	± 1.21	± 1.66	± 3,55	± 047
		(5)	(5)	(5)	(5)	(5)	(5)
		35 52	31 54	35 14	32.16	35.14	33 34
	14	± 3.57	± 4.65	± 1 38	± 5.03	= 250	± 1 14
		(5)	(5)	(5)	(5)	(5)	(5)
		21.14	21 08	21 32	21.20	21.02	21 42
	0	± 060	± 0.78	± 0.71	± 0.70	= 0.54	± 0.61
		(5)	(5)	(5)	(5)	(5)	(5)
		26.04	27 22	26.82	25.60	26.80	26.18
Female	7	± ~ 78	± 0.53	± 1.26	± 0.90	≖ 0.88	± 0 ()
		(5)	(5)	(5)	(5)	(5)	(5)
		27.68	29 12	28.06	28.46	25 96	27 86
	14	± 0.99	± 1.27	± 0.80	± 0.47	= 3 13	± 1.02
		(5)	(5)	(5)	(5)	(5)	(5)

Table 4. Gross finding of male ICR mice administered intragastrically with Geranti-germanium

<u>-</u>			Dose(nig/kg)		
	5,000	2.500	1.250	625	312 5	control
Brain						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Kidney-L						
No of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Kidney-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Heart						•
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Lung				•	-	ŭ
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Spleen		-	_	Ū	Ŭ	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Liver		-	-	•	Ü	J
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-L		_	_	J	J	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-R		_	_	Ū	J	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Pituitary gland	Ū	J	9	3	5	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Testis-L	· ·	J	J	•	5	J
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5 5
restis-R	Ū	J	J	J	J	J
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5 5	5 5	5 5	5 5
other organs	J	J	J	J	J	Э
No. of observations	5	5	5	5	E	-
No gross findings	5	5	5	5 5	5 5	5 5

Table 5. Gross findings of female ICR mice administered intragastrically with Geranti-germanium

			Dose(mg/kg)		
	5,000	2,500	1,250	625	312.5	control
Brain						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Kidney-L						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Kidney-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Heart						
No. of observations	5	5	5	. 5	5	5
No gross findings	5	5	5	5	5	5
Lung						•
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Spleen				•	· ·	Ŭ
No. of observations	5	5	5	5	5	5
No gro _ findings	5	5	5	5	5	5
Liver		-	-	•	ŭ	v
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-L	-	Ū	J	J	3	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-R	Ū	J	J	J	3	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Pituitary gland	Ū	Ü	J	3	3	3
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	• 5	5	5
Testis-L	J	3	J	3	3	5
No. of observations	5	5	5	5	5	5
No gross findings	5	<i>5</i>	5 5	5 5	5 5	5 5
Testis-R	J	J	J	3	5	5
No. of observations	5	5	5	E	E	
No gross findings	5	5	5 5	5 5	5	5
other organs	5	5	J	5	5	5
No of observations	E	_	-	r	-	_
	5 5	5	5	5	5	5
No gross findings	5	5	5	5	5	5

Discussion

Geranti-germanium was natural products with Saccharomyes cerevisiae containing organic germanium that is biosynthesized in yeast cell. This organic germanium is chemically connected inorganic germanium ions with organic compound such as amino acid or organic acid. Also it is contain a very small amount as a trace element in the plant, animal and living body. From this century, organic germanium have been known the therapeutic effect on incurable disease including cancer, hypertension, diabetes, heart disease, regressive disease, arthritis and show immune enhancement and detoxification of heavy metals. So Recently, The research for incurable disease, especially in cancer and heart disease, using organic germanium is actively progressing in America, Japan and other countnes. In the ways to get organic germanium for human being, one is extracting from the natural product like Ginseng, Formes japonicus etc. And the other is chemical synthesis through reaction of organic acid and germanium dioxide by catalyst. But the former is not cost effective while the other is not completely safe as foods or medicines. Meanwhile, Yeast, as a widely used for brewing, breaking, is not only much affected in diet for several thousand years but also is using widely as a source of supply with rich nutritious containing proteins, vitamins, minerals oneself. Hence, Geranti Pharm Ltd. as a result of research for organic germanium was developed the method of mass production of safe organic germanium using yeast

In the study, in order to examine the acute oral toxicity of Geranti permanium in mice since the maximum dosage was 5,000mg/kg. The maximum dosages that can be administrate in both sexes of mice using Sonde into the stomach one times and observed for 14 days. The example of death was not observed in all tests group and impossible the calculation of LD₅₀ value. Also it was not observed the change of body weight and clinical symptoms in case the autopsy too. From the whole result, Geranti-germanium was considered as safe material to mice that it was free from hamful. And it was not observed the pathological view since there are no significant clinical symptoms and the example of death.

References

- 1" The standard of toxicity test for pharmaceuticals"(March 14, 1994, an established by law) that is the regulation (94-3) of the National Sanitation and Safety Research Institute
- 2 Int J. Radiat Biol. Relat. Stud. Phy. Chem. Med 42(6): 653-659(1982)
- 3. Anticancer Res., 5(5): 479-483(1985)

2. An acute oral toxicity test of Geranti-Germanium in rat

Materials and Method

1. Test Material

Name: Geranti-Germanium
 Molecular structure. unknown
 Chemical name: unknown
 Appearance: a yellow powder

5) pH:6~8

6) The condition of storage: under 4 degree C

2. The experimental animal

In this test, we were selected SD rat, because SD rat have been widely used in toxicity test including acute, subacute and chronic toxicity test. And there are many the physiology autopsy and toxicological data on SD rat. We were used only healthful rats without the decrease of the weight among the laboratory animal that made quarantine and acclimation in laboratory for a week. The discrimination of individual was append a label that is stated the name of responsible person, the period of test, dosage, the number of rat, test number in cage for breeding.

The rat were breed a five head each the cage of breeding in polycarbonate cage (175W× 240L

× 145Hmm) during the tem; of testing and acclimation.

3. The dosage and the test group

The maximum dosage was set up as $5000 \, \mathrm{mg}$ per $\, \mathrm{kg}$ and dosage volume was $0.2 \, \mathrm{ml/10g}$ body weight. And Geranti-germanium was diluted in the regular rate (0.5 ratio) with distilled water standardizing this dosage and set up the group of five. The composition of the test group, dosage and liquid measure were the following

The material of administration	The test group	sex	The No. of animal	The animal No.	Dosage (mg/kg)	liquid measure (ml/Kg B.W)
	GA1	М	5	GAM 1 - GAM 5	5,000	20
		F	5	GAF 1 - GAF 5		
	GA2	М	5	GAM 6 - GAM 10	2,500	20
		F	5	GAF 6 - GAF 10)
Dilute JY with	GA3	М	5	GAM 11 - GAM 15	1,250	20
D. W.		F	5	GAF 11 - GAF 15		
	GA4	M	5	GAM16 - GAM 20	625	20
		F	5	GAF 16 - GAF 20		,
	GA5	М	5	GAM21 - GAM 25	312.5	20
		F	5	GAF 21 - GAF 25		
Control group	CAE	М	5	GAM 26 - GAM 30		00
(D. W.)	GA6	F	5	GAF 26 - GAF 30	0	20

G: Intragastrically, A: Acute, M: Male, F: Female

4 The administration of test material

1) The preparation of test solution

We were prepared the test solution that was diluted in distilled water just before administration and the germanium content measured by phenylfluorone method.

2) The route and the method of administration

We were selected oral administration on the basis of the acute toxicity test method. In rat case, administrate in the stomach using the Sonde. The calculation of dosage was fixed on the basis of body weight. And the powder of Geranti was dissolved in distilled water. It was administered only distilled water in control group. And the maximum dosage was set up 5000 mg/kg and administrate to rat.

5. The observation

The day of administration was observed the general symptoms from the first day to fourteenth day including the change of general state, the symptoms of poisoning, motility, appearance, and whether animal was died or not. The body weight was measured as mean value from three times in just before autopsy (after 14 days), after seventh days and just before the administration on all rats. The LD₅₀ was calculated by the method of Litechfield-Wilcoxon using computer program pharmacological calculation system version4.1.

Result

(1) LD₅₀ value

When this test material was administrated oral to male and female rat. The example of death was not observed in the maximum dose of $5000 \, \text{mg}$ per kg (0.2ml/10g B.W.). So the calculation of LD₅₀ value was impossible.

(2) The death rate (Table 1)

In case of oral administration, the example of death was not observed during the test period in both sexes.

(3) Clinical symptoms (Table 2)

The unique clinical symptom due to test material was not observed during the test period in both sexes.

(4) The change of body weight (Table 3)

The significant change of body weight in each group was not observed during the test period in both sexes.

(5) The view of autopsy (Table 4)

It was not observed the pathological abnormality due to this material in the autopsy of survival rat.

(6) The histopathological view

The significant histopathological sign was not observed in the autopsycof survival rat.

Table 1. Mortality of male and female SD Rat administered intragastrically with Gerantigermanium

Cov	Dose	Ho	urs	рс	st-	trea	ıtm	ent				[Эау	s a	fter	tre	atr	ner	ıt				Final
Sex	(mg/kg)	1	2	3	4	5	6	12	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Mortality
	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	2,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
Male	1,250	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
IVIAIC	625	0	0	0	0	0	0	0	0	0	0	0	0	0	Ó	0	0	0	0	0	0	0	0/5
	312.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0.	0	0	0	0	0	0	0	0/5
	0(Control)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	5,000	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	2,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
Fe-	1,250	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
male	625	0	0	0	0	0	0	0	0	0	0	0	0	0	, 0	0	0	0	0	0	0	0	0/5
	312.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5
	0(Control)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0/5

Table 2. Clinical Findings of Male and Female SD rat administered intragastrically with Gerantigermanium

Sex	Dose	Findings	Но	urs	aft	er t	rea	tme	ent				Da	ys	afte	r tr	eat	me	nt				
Sex	(mg/kg)	munigs	1	2	3	4	5	6	12	1	2	3	4	5	6	7	8	9	10	11	12	13	14
	5,000	N	5	5	5	5	5	`5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	5,000	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	2 500	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	2,500	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	4.050	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	1,250	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
М	005	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	625	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	040.5	Ν	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	312.5	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	0	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	(Control)	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	5,000	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	2,500	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
_	1,250	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
F		Ν	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	625	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	312.5	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	0	N	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
	(Control)	-	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

M : Male, F :Female

N : No. of animals examined
- No. Abnormality detected

Table 3. Body Weights of male and female SD rat administered intragastrically with Geranti-germanium (Mean ± SD : g)

	Days after			Dose(mg/kg)		
Sex	treatment	5,000	2,500	1,250	625	312.5	control
		25.68	24.96	25.34	25.08	25.48	25.56
	0	± 0.36	± 0.40	± 0.52	± 0.45	= 0.73	± 0.59
		(5)	(5)	(5)	(5)	(5)	(5)
		33.38	30.58	33.90	33.02	30.80	29 36
Male	7	± 2.56	± 4.10	± 1.21	± 1.66	± 3.55	± 0.47
		(5)	(5)	(5)	(5)	(5)	(5)
		35.52	31.54	35.14	32.16	35.14	33.34
	14	± 3.57	± 4.65	± 1.38 ,	± 5.03	± 2.50	± 1.14
		(5)	(5)	(5)	(5)	(5)	(5)
		21.14	21.08	21.32	21.20	21.02	21.42
	0	± 0.60	± 0.78	± 0.71	± 0.70	± 0.54	± 0.61
		(5)	(5)	(5)	(5)	(5)	(5)
		26.04	27.22	26.82	25.60	26.80	26.18
Fe.nale	7	± 0.78	± 0.53	± 1.26	± 0.90	± 0.88	± 0.65
		(5)	(5)	(5)	(5)	(5)	(5)
,		27.68	29.12	28.06	28.46	25.96	27.86
	14	± 0.99	± 1.27	± 0.80	± 0.47	± 3.13	± 1.02
		(5)	(5)	(5)	(5)	(5)	(5)

Table 4. Gross finding of male SD rat administered intragastrically with Geranti-germanium.

	-		Dose	e(mg/kg)		
-	5,000	2,500	1,250	625	312.5	Control
Brain						
No. of observations	5	5	5	5	5	5
No gross findings	5	· 5	5	5	5	5
Kidney-L						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	. 5	5
Kidney-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Heart						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5 ·	5	5	5
Lung						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Spleen						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Liver						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	. <u>5</u> 5	5	5
Adrenal gland-L	•					
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Pituitary gland						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5 .	5	5	5
Testis-L			•			
No. of observations	5	5	5	5	5	5
No gross findings	5	5	. 5	5	5	5
Testis-R	-	-	-	-	-	_
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Other organs	·	-	-	-	-	_
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5

Table 5. Gross findings of female SD Rat administered intragastrically with Geranti-germanium

	Dose(mg/kg)					
•	5,000	2,500	1,250	625	312.5	Control
Brain						
No. of observations	5	5 ·	5	5	5	5
No gross findings	5	5	5	5	5	5
Kıdney-L						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Kidney-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Heart						
No. of observations	5	5	5	· 5	5	5
No gross findings	5	5	5	5	5	5
Lung						-
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Spleen						•
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Liver						_
No. of observations	5	5	5 `	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-L						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Adrenal gland-R						
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Pituitary gland						-
No. of observations	5	5	5	, 5	5	5
No gross findings	5	5	5	5	5	5
Testis-L					•	-
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Testis-R					-	-
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5
Other organs					•	•
No. of observations	5	5	5	5	5	5
No gross findings	5	5	5	5	5	5

Discussion

Geranti-germanium was natural products with Saccharomyes cerevisiae containing organic germanium that is biosynthesized in yeast cell. This organic germanium is chemically connected inorganic germanium ions with organic compound such as amino acid or organic acid. Also it is contain a very small amount as a trace element in the plant, animal and living body. From this century, organic germanium have been known the therapeutic effect on incurable disease including cancer, hypertension, diabetes, heart disease, regressive disease, arthritis and show immune enhancement and detoxification of heavy metals. So Recently, The research for incurable disease, especially in cancer and heart disease, using organic germanium is actively progressing in America, Japan and other countries. In the ways to get organic germanium for human being, one is extracting from the natural product like Ginseng, Formes japonicus etc. And the other is chemical synthesis through reaction of organic acid and germanium dioxide by catalyst. But the former is not cost effective while the other is not completely safe as foods or medicines. Meanwhile, Yeast, as a widely used for brewing, breaking, is not only much affected in diet for several thousand years but also is using widely as a source of supply with rich nutritious containing proteins, vitamins, minerals oneself. Hence, Geranti Pharm Ltd. as a result of research for organic germanium was developed the method of mass production of safe organic germanium using yeast.

In this study, in order to examine the acute oral toxicity of Geranti-germanium in rat since the maximum dosage was 5,000mg/kg. The maximum dosages that can be administrate in both sexes of rat using Sonde into the stomach one times and observed for 14 days. The example of death was not observed in all tests group and impossible the calculation of LD₅₀ value. Also it was not observed the change of body weight and clinical symptoms in case the autopsy too. From the whole result, Geranti-germanium was considered as safe material to rat that it was free from hamful. And it was not observed the pathological view since there are no significant clinical symptoms and the example of death.

References

- 1" The standard of toxicity test for pharmaceuticals" (March 14, 1994, an established by law) that is the regulation (94-3) of the National Sanitation and Safety Research Institute.
- 2. Int. J. Radiat. Biol. Relat. Stud. Phy. Chem. Med 42(6): 653-659(1982)
- 3. Anticancer Res., 5(5): 479-483(1985)